Faculty profile

Taha Azad

ResearcherMicrobiology and Infectious DiseasesUniversité de Sherbrooke

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Sherbrooke directory, so their courses may be missing. Find their university profile.

Taha Azad

Researcher

Microbiology and Infectious Diseases

Health Sciences

Université de Sherbrooke

Sherbrooke, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
13 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2025.
Supervisor on 2 trainee awards (2 CIHR), most recently in 2026.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cancer Immunotherapy Oncolytic Viruses Synthetic Biology Cancer Cancer, Genome Editing Crispr/Cas9 Immunotherapy Next Generation Sequencing

Latest papers

Biosensor-guided discovery of peptide inhibitors targeting the ribosomal protein uS5-PDCD2 chaperone interaction.
The Journal of biological chemistry · 2026
Artificial Intelligence Reveals Nature: Functional Parallels Between a Designed and a Natural Peptide.
International journal of molecular sciences · 2025
Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.
Nature biomedical engineering · 2025 · senior author

All 13 publications

Latest funding

Unlocking the Potentials of RNA Therapeutics by Tuning Innate Immunity
CIHR · 2026 · Supervisor
$140,000
Harnessing Antibiotics for Rapid Optimization of Cancer-Specific Vaccinia Oncolytic Virus
CIHR · 2025 · Nominated PI
$1,139,850
Development of an NLRC5-based broad spectrum immunotherapeutic for immune evasive cancers
CIHR · 2025 · Co-investigator
$1,181,926

All 7 grants and awards

13 publications.

Biosensor-guided discovery of peptide inhibitors targeting the ribosomal protein uS5-PDCD2 chaperone interaction.

Mir Hassani Z, Goulet F, Nguyen DT, Landry-Voyer AM, Kwiatek L, Gaudet S, Boudreault PL, Azad T, Bachand F

The Journal of biological chemistry2026

DOI: 10.1016/j.jbc.2026.111415 PMID: 41933732

Artificial Intelligence Reveals Nature: Functional Parallels Between a Designed and a Natural Peptide.

Wang J, Kazmirchuk TDD, Hajikarimlou M, Al-Gafari M, Takallou S, Moteshareie H, Dehne F, Samanfar B, Babu M, Azad T, Golshani A

International journal of molecular sciences2025

DOI: 10.3390/ijms262110607 PMID: 41226643

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.

Rezaei R, Boulton S, Ahmadi M, Petryk J, Da Silva M, Kooshki Zamani N, Singaravelu R, St-Laurent G, Daniel L, Sadeghipour A, Pelin A, Poutou J, Munoz Zuniga AI, Choy C, Gilchrist VH, Khalid Z, Austin B, Onsu KA, Marius R, Ameli Z, Mohammadi F, Mancinelli V, Wang E, Nik-Akhtar A, Alwithenani A, Panahi Arasi F, Ferguson SSG, Hobman TC, Alain T, Tai LH, Ilkow CS, Diallo JS, Bell JC, Azad T

Nature biomedical engineering2025Senior author

DOI: 10.1038/s41551-024-01259-7 PMID: 39609558

Oxidative stress-induced YAP1 expression is regulated by NCE102, CDA2, and BCS1.

Takallou S, Hajikarimlou M, Al-Gafari M, Wang J, Jagadeesan SK, Kazmirchuk TDD, Arnoczki C, Moteshareie H, Said KB, Azad T, Holcik M, Samanfar B, Smith M, Golshani A

The FEBS journal2024

DOI: 10.1111/febs.17243 PMID: 39102301

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer.

Hoshi R, Gorospe KA, Labouta HI, Azad T, Lee WL, Thu KL

Pharmaceutics2024

DOI: 10.3390/pharmaceutics16091181 PMID: 39339217

Hydrogen peroxide sensitivity connects the activity of COX5A and NPR3 to the regulation of YAP1 expression.

Takallou S, Hajikarimlou M, Al-Gafari M, Wang J, Jagadeesan SK, Kazmirchuk TDD, Moteshareie H, Indrayanti AM, Azad T, Holcik M, Samanfar B, Smith M, Golshani A

FASEB journal : official publication of the Federation of American Societies for Experimental Biology2024

DOI: 10.1096/fj.202300978rr PMID: 38416461

Recent progress in combination therapy of oncolytic vaccinia virus.

Mirbahari SN, Da Silva M, Zúñiga AIM, Kooshki Zamani N, St-Laurent G, Totonchi M, Azad T

Frontiers in immunology2024Senior author

DOI: 10.3389/fimmu.2024.1272351 PMID: 38558795

Ultrasensitive detection of vital biomolecules based on a multi-purpose BioMEMS for Point of care testing: digoxin measurement as a case study.

Marvi F, Jafari K, Shahabadi M, Tabarzad M, Ghorbani-Bidkorpeh F, Azad T

Scientific reports2024Senior author

DOI: 10.1038/s41598-024-51864-4 PMID: 38238435

Comparative Analysis of Cyclization Techniques in Stapled Peptides: Structural Insights into Protein-Protein Interactions in a SARS-CoV-2 Spike RBD/hACE2 Model System.

Ferková S, Froehlich U, Nepveu-Traversy MÉ, Murza A, Azad T, Grandbois M, Sarret P, Lavigne P, Boudreault PL

International journal of molecular sciences2023

DOI: 10.3390/ijms25010166 PMID: 38203338

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.

Boulton S, Poutou J, Gill R, Alluqmani N, He X, Singaravelu R, Crupi MJF, Petryk J, Austin B, Angka L, Taha Z, Teo I, Singh S, Jamil R, Marius R, Martin N, Jamieson T, Azad T, Diallo JS, Ilkow CS, Bell JC

Molecular therapy. Methods & clinical development2023

DOI: 10.1016/j.omtm.2023.101110 PMID: 37822719

Unlocking the Potentials of RNA Therapeutics by Tuning Innate Immunity

SupervisorCIHR2026Fellowship: Canada Impact+ Research Training Awards - Postdoctoral

Principal investigators: Khani Khouzani, Leila

Keywords: Rna Vaccine; Cancer; Immunotherapy; Rna Therapeutic; Self-Amplifying Rna

$140,000

Harnessing Antibiotics for Rapid Optimization of Cancer-Specific Vaccinia Oncolytic Virus

Nominated PICIHR2025Project Grant

Principal investigators: Azad, Taha

Keywords: Cancer; Cancer Immunotherapy; Oncolytic Viruses; Synthetic Biology

$1,139,850

Development of an NLRC5-based broad spectrum immunotherapeutic for immune evasive cancers

Co-investigatorCIHR2025Project Grant

Principal investigators: Ilangumaran, Subburaj; Ramanathan, Sheela

Keywords: Antigen Presentation; Cd8+ T Cells; Mhc Class-I; Mhc-I Peptide; Nlrc5; Oncolytic Virotherapy; Proteomics; Tumor Immune Evasion

$1,181,926

Improving Breast Cancer Treatment with Safer and More Effective Oncolytic Viruses

SupervisorCIHR2025DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Principal investigators: Ahmadi, Mahsa

Keywords: Breast Cancer; Cancer Biology; Immunotherapy; Oncolytic Virotherapy; Synthetic Virology; Vaccine For Cancer

$120,000

Precision virotherapy to treat bladder cancer

Co-investigatorCIHR2024Project Grant

Principal investigators: Tai, Lee-Hwa

Keywords: Bcg Failure; Bladder Cancer; Bladder-Sparing Therapy; Cytokines; Immunomodulation; Immunotherapy; Mouse Models; Translational Research; Tumor Immune Microenvironment; Virotherapy

$814,726

Harnessing blood-derived immune cells to overcome challenges in TIL therapy

Co-investigatorCIHR2024Project Grant

Principal investigators: Tai, Lee-Hwa

Keywords: Immune Suppression; Immunomodulation; Immunotherapy; Metastasis; Organoids; Poor Prognosis Cancers; Translational Research; Triple Negative Breast Cancer; Tumor Immune Microenvironment; Virotherapy

$1,009,800

Bioengineering viruses to create safer and more effective oncolytic viruses

Nominated PICIHR2023Project Grant

Principal investigators: Azad, Taha

Keywords: Cancer Immunotherapy; Cancer, Genome Editing; Crispr/Cas9; Immunotherapy; Next Generation Sequencing; Oncolytic Viruses; Screening; Synthetic Biology; Vaccines

$986,850

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Taha Azad

Research

Latest papers

Latest funding

Biosensor-guided discovery of peptide inhibitors targeting the ribosomal protein uS5-PDCD2 chaperone interaction.

Artificial Intelligence Reveals Nature: Functional Parallels Between a Designed and a Natural Peptide.

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.

Oxidative stress-induced YAP1 expression is regulated by NCE102, CDA2, and BCS1.

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer.

Hydrogen peroxide sensitivity connects the activity of COX5A and NPR3 to the regulation of YAP1 expression.

Recent progress in combination therapy of oncolytic vaccinia virus.

Ultrasensitive detection of vital biomolecules based on a multi-purpose BioMEMS for Point of care testing: digoxin measurement as a case study.

Comparative Analysis of Cyclization Techniques in Stapled Peptides: Structural Insights into Protein-Protein Interactions in a SARS-CoV-2 Spike RBD/hACE2 Model System.

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.

Unlocking the Potentials of RNA Therapeutics by Tuning Innate Immunity

Harnessing Antibiotics for Rapid Optimization of Cancer-Specific Vaccinia Oncolytic Virus

Development of an NLRC5-based broad spectrum immunotherapeutic for immune evasive cancers

Improving Breast Cancer Treatment with Safer and More Effective Oncolytic Viruses

Precision virotherapy to treat bladder cancer

Harnessing blood-derived immune cells to overcome challenges in TIL therapy

Bioengineering viruses to create safer and more effective oncolytic viruses

Frequent collaborators

Abolfazl Nik-Akhtar

Martin Holcik

Jean-Simon Diallo

Lee-Hwa Tai

Tommy Alain

Pierre-Luc Boudreault

Jaahnavi Dave

Iris Teo

Peter Greer

Michele Ardolino

Philippe Sarret

Mohan Babu

Pierre Lavigne

Taha Azad

Research

Latest papers

Latest funding

Biosensor-guided discovery of peptide inhibitors targeting the ribosomal protein uS5-PDCD2 chaperone interaction.

Artificial Intelligence Reveals Nature: Functional Parallels Between a Designed and a Natural Peptide.

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.

Oxidative stress-induced YAP1 expression is regulated by NCE102, CDA2, and BCS1.

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer.

Hydrogen peroxide sensitivity connects the activity of COX5A and NPR3 to the regulation of YAP1 expression.

Recent progress in combination therapy of oncolytic vaccinia virus.

Ultrasensitive detection of vital biomolecules based on a multi-purpose BioMEMS for Point of care testing: digoxin measurement as a case study.

Comparative Analysis of Cyclization Techniques in Stapled Peptides: Structural Insights into Protein-Protein Interactions in a SARS-CoV-2 Spike RBD/hACE2 Model System.

A T&#xa0;cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.

Unlocking the Potentials of RNA Therapeutics by Tuning Innate Immunity

Harnessing Antibiotics for Rapid Optimization of Cancer-Specific Vaccinia Oncolytic Virus

Development of an NLRC5-based broad spectrum immunotherapeutic for immune evasive cancers

Improving Breast Cancer Treatment with Safer and More Effective Oncolytic Viruses

Precision virotherapy to treat bladder cancer

Harnessing blood-derived immune cells to overcome challenges in TIL therapy

Bioengineering viruses to create safer and more effective oncolytic viruses

Frequent collaborators

Abolfazl Nik-Akhtar

Martin Holcik

Jean-Simon Diallo

Lee-Hwa Tai

Tommy Alain

Pierre-Luc Boudreault

Jaahnavi Dave

Iris Teo

Peter Greer

Michele Ardolino

Philippe Sarret

Mohan Babu

Pierre Lavigne

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.